-The Economic Times NEW DELHI: Top-selling blood pressure drugs and antibiotics could become a lot cheaper as the government plans to notify price caps for 51 essential drugs early next week under a new drug price control order that was enforced last month. Under this second lot of notifications by the National Pharma Pricing Authority, the brands selling the most expensive antibiotics would have to cut their prices by 30-60%. For instance, the...

-The Times of India NEW DELHI: A United Nations (UN) report has warned India that it is at greater risk by opting for public private partnership (PPP) mode of investment for raising its public infrastructure where the government has less control over its executing private partners and the latter has little interest in long term safety of the projects. A UN study, the Global Assessment Report (GAR) on disaster risk reduction, released...

-The Telegraph Kolkata: Sebi has barred Alchemist Infra Realty Ltd from continuing its collective investment scheme and ordered that investors, several of whom are said to be in Bengal, be refunded within three months. The capital market watchdog's order said the company had denied it had anything to do with Alchemist Group, which is run by the family of K.D. Singh, a Rajya Sabha member from the Trinamul Congress. Some party Leaders...

-The Business Standard Data also show that several other Leading domestic pharma companies have recalled their products from the US Frequent drug recalls, warning letters and import alerts from the US in the recent past have turned into a major concern for the Indian pharmaceutical industry and investors. While Ranbaxy Laboratories recently pLeaded guilty before the US authorities for its wrongdoings in the past, the crackdown on the drug companies seems to...

-The Hindu Even as the Union government rejected reports of shortage of tuberculosis drugs, saying fresh stocks will arrive by July-end, World Health Organisation (WHO) on Friday asked India to consider changing the regimen from intermittent to daily doses. One of the challenges in anti-TB drugs procurement is that only a few manufacturers produce the particular regimen used by India's programme, which is of intermittent schedule. "WHO currently recommends governments to consider...